12:00 AM
 | 
Jan 21, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Telintra ezatiostat hydrochloride regulatory update

Telik said FDA granted Orphan Drug designation for Telintra ezatiostat hydrochloride to treat myelodysplastic syndrome (MDS). An...

Read the full 64 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >